We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00801515
Recruitment Status : No longer available
First Posted : December 3, 2008
Last Update Posted : July 25, 2011
Information provided by:

December 2, 2008
December 3, 2008
July 25, 2011
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.
Not Provided
Expanded Access
Drug: Maraviroc
150 mg twice per day
Other Name: Celsentri
Not Provided
No longer available
Contact information is only displayed when the study is recruiting subjects
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ViiV Healthcare
Study Director: Pfizer CT.gov Call Center Pfizer
ViiV Healthcare
July 2011